Bayer Schering Pharma voices commitment to oncology field

Bayer Schering Pharma is committed to expanding its oncology franchise, it has asserted.

The company is currently investigating a novel anti-cancer development candidate known as BAY 73-4506 (DAST-Inhibitor).

It is being studied to see how effective it is treating patients with advanced refractory colorectal carcinoma, as well as those with metastatic or unresectable renal cell cancer.

Kemal Malik is head of global development at Bayer Schering Pharma and noted the compound is one of the most promising in the company’s pipeline.

He commented: “We look forward to determining the role of BAY 73-4506, along with other compounds in our franchise, in creating potential treatment options for patients afflicted with various cancers.”

Between May 29th and June 2nd, data from investigations of the development will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology.

Earlier this month, Bayer Schering Pharma discussed results from trials of an oral agent riociguat called BAY 63-2521, which is designed to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

The presentation was held at the American Thoracic Society international conference.